Stocktoria
TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.01% (safety: no dividend). FY2025 revenue was $17.3B at a 8.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.34 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-12 | Barclays | Overweight (main) |
| 2026-07-28 | Piper Sandler | Overweight (main) |
| 2026-05-06 | Barclays | Overweight (main) |
| 2026-04-30 | JP Morgan | Overweight (main) |
| 2026-04-30 | UBS | Buy (main) |
| 2026-04-30 | Piper Sandler | Overweight (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.012 |
| Retained earnings / assets | -0.338 |
| EBIT / assets | 0.053 |
| Equity / liabilities | 0.241 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 7/9 | -0.41 | 84.8 | +4.3% |
| UPC | Universe Pharmaceuticals INC | 4/9 | 7.37 | — | -22.4% |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
About TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
FAQ
Is TEVA financially healthy?
TEVA PHARMACEUTICAL INDUSTRIES LTD's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TEVA pay a dividend, and is it safe?
Yes. TEVA PHARMACEUTICAL INDUSTRIES LTD pays a dividend yielding about 0.01% with a None payout ratio, rated “no dividend” for safety.
How profitable is TEVA?
In FY2025, TEVA PHARMACEUTICAL INDUSTRIES LTD had a net margin of 8.2% and a return on equity of 17.8%.
Is TEVA overvalued or undervalued?
TEVA PHARMACEUTICAL INDUSTRIES LTD trades at about 30.4× trailing earnings — near its 10-year norm (10-year range 14.6×–477.6×, median 28.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for TEVA?
The average Wall-Street price target for TEVA PHARMACEUTICAL INDUSTRIES LTD is $41.20, about 12.1% above the recent price, from 10 analysts (consensus: strong buy).
Is TEVA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TEVA PHARMACEUTICAL INDUSTRIES LTD: a Piotroski F-score of 7/9, an Altman Z″ in the distress zone, a P/E of about 84.8×, a dividend yield of 0.01%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.